Chin J Schisto Control ›› 2011, Vol. 23 ›› Issue (6): 701-703.

Previous Articles     Next Articles

Therapeutic effect of Dahuangzhechong pills on advanced schistosomiasis

Niu Xue-hua1, Wu Peng-fei1, Hua Hai-yong2, Huang Li-hua3, Wu Hang-yuan3, Zhu Hong -ying3, Yang Xiao-juan3, Yao Shang-zhi3, Li Yan-guang3, Qiu Yuan-wang3*   

  1. 1 Third Hospital of Kunshan, Jiangsu Province, Kunshan 215300| China|2 Jiangsu Provincial Institute of Parasitic Diseases, China|3 Wuxi Infectious Disease Hospital, Jiangsu Province, China
  • Online:2011-12-22 Published:2011-12-14
  • Contact: Qiu Yuan?wang

大黄蛰虫丸治疗晚期血吸虫病临床疗效

牛雪花1|吴鹏飞1|华海涌2|黄利华3|吴杭源3|朱宏英3|杨小娟3|姚上志3|李焱光3|邱源旺3*   

  1. 1 江苏省昆山市第三人民医院 (昆山 215300); 2 江苏省寄生虫病防治研究所; 3 江苏省无锡市传染病医院
  • 通讯作者: 邱源旺
  • 作者简介:牛雪花|女|本科|主治医师。研究方向:血吸虫病诊断与治疗
  • 基金资助:

    江苏省卫生厅血地寄防应用性科研课题 (X200913)

Abstract:

Objective To evaluate the therapeutic effect and safety of Dahuangzhechong pills on advanced schistosomiasis. Methods Sixty?two patients with advanced schistosomiasis were divided randomly into two groups, a treatment group and a control group, and treated with Dahuangzhechong pills and routine therapy, respectively. The course of treatment was 52 weeks in the two groups. Before and after the 52?week treatment, the indexes of liver function and hepatic fibrosis, prothrombin time(PT) , Child ?Pugh scores and changes of B?type ultrasonic images were detected for all the patients. Results There were significant differences in the levels of alanine aminotransferase (ALT) and total bilirubin (TBIL), the indexes of hepatic fibrosis, portal venous inside diameters and portal venous flow between the two groups after 52 weeks treatment (P < 0.05). In addition, there were no obvious adverse effects during the treatment in the patients of the Dahuangzhechong pill group. Conclusion Dahuangzhechong pill treatment is a safe and effective therapy for the patients with advanced schistosomiasis.

Key words: Advanced schistosomiasis, Hepatic fibrosis, Dahuangzhechong pill, Therapeutic effect

摘要:

目的 观察大黄蛰虫丸治疗晚期血吸虫病的疗效及安全性。 方法 确诊的62例晚期血吸虫病患者随机分为治疗组和对照组2组, 每组31例, 分别采用大黄蛰虫丸和常规治疗, 疗程均为52周, 观察治疗前后患者肝功能、 肝纤维化指标、 肝脏B超影像学的变化。结果 大黄蛰虫丸治疗组患者治疗52周后丙氨酸氨基转移酶、 总胆红素、 肝纤维化指标及B 超门静脉内径、 门静脉血流量均较对照组有明显改善, 差异均有统计学意义(P 均<0.05)。大黄蛰虫丸治疗组患者治疗过程中未出现严重不良反应。结论 大黄蛰虫丸治疗晚期血吸虫病安全有效。

关键词: 晚期血吸虫病;肝纤维化;大黄蛰虫丸;疗效

CLC Number: